# EDGAR Filing Document

**Accession Number:** 0001971387
**File Stem:** 0000000000-26-000092
**Filing Date:** 2026-1
**Character Count:** 2504
**Document Hash:** 0fdb3a5dd6046e9a298429d701b756a9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-000092.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0000000000-26-000092

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260106

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Liminatus Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001971387
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08901

**BUSINESS ADDRESS:**
- **STREET 1:** 12611 HIDDENCREEK WAY
- **STREET 2:** UNIT C
- **CITY:** CERRITOS
- **STATE:** CA
- **ZIP:** 90703
- **BUSINESS PHONE:** 213-273-5453

**MAIL ADDRESS:**
- **STREET 1:** 12611 HIDDENCREEK WAY
- **STREET 2:** UNIT C
- **CITY:** CERRITOS
- **STATE:** CA
- **ZIP:** 90703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Iris Parent Holding Corp.
- **DATE OF NAME CHANGE:** 20230328
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-25-125670

## Text-Extract

```

                                                            January 6, 2026

Chris Kim
Chief Executive Officer and Director
Liminatus Pharma, Inc.
12611 Hiddencreek Way, Unit C
Cerritos, CA 90703

       Re: Liminatus Pharma, Inc.
           Draft Registration Statement on Form S-1
           Submitted December 31, 2025
           CIK No. 0001971387
Dear Chris Kim:

       This is to advise you that we do not intend to review your registration
statement.

        We request that you publicly file your registration statement and
non-public draft
submission on EDGAR at least two business days prior to the requested effective
date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We
remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Giovanni Caruso, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._